石药集团(01093.HK) 公布,附属巨石生物开发的司库奇尤单抗注射液在用于治疗中度至重度斑块状银屑病的等效性III期临床试验中获得顶线分析数据。该产品是集团开发的全人源Ig G1单克隆抗体药物,为司库奇尤单抗注射液(可善挺)的生物类似药。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-18 16:25。)AASTOCKS新闻
Source Link石药集团(01093.HK) 公布,附属巨石生物开发的司库奇尤单抗注射液在用于治疗中度至重度斑块状银屑病的等效性III期临床试验中获得顶线分析数据。该产品是集团开发的全人源Ig G1单克隆抗体药物,为司库奇尤单抗注射液(可善挺)的生物类似药。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-18 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.